Here's another post from Derek Lowe's In the Pipeline blog that continues discussing where our drugs come from - pharma, biotech or univerisities. This installment is focused on the countries of origin. The upshot is the US leads with more drugs designed to meet unmet-medical-needs, especially from its biotech and university sector. International biotech drugs are virtually absent which I thought was interesting. To me, that may be a signal to indeed extend the R&D tax credit to biotechs to further support our worldwide lead in drug innovation.
Here's the entire In the Pipeline post.
Posted by Bruce Lehr November 9th 2010.